ASCO CLL Spotlight

iFCG Regimen Induces High Rate of Bone Marrow MRD Negativity in IGHV-Mutated CLL

June 22, 2017

The combination regimen of ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab achieved a high rate of minimal residual disease-negative status in bone marrow as a first-line treatment in patients with IGHV-mutated chronic lymphocytic leukemia

Ibrutinib Shows Strong PFS and OS Benefits in RESONATE Study Follow-Up

June 21, 2017

The BTK inhibitor ibrutinib continued to demonstrate sustained progression-free survival and overall survival in chronic lymphocytic leukemia, regardless of patients’ high-risk cytogenetic status.

Obinutuzumab/Bendamustine Combo Shows Promising Response Rates in Upfront CLL

June 21, 2017

The combination of the anti-CD20 monoclonal antibody obinutuzumab and bendamustine induced high rates of complete response and minimal residual disease negativity with no unexpected safety signals as a first-line therapy for patients with chronic lymphocytic leukemia.

The Potential of Ibrutinib Combinations for the Treatment of CLL

June 16, 2017

Javier Pinilla-Ibarz, MD, PhD, associate member, Malignant Hematology and Immunology Program at the H. Lee Moffitt Cancer Center, discusses ongoing research with ibrutinib (Imbruvica) in chronic lymphocytic leukemia.

Concurrent Treatment With CAR T-Cells, Ibrutinib Leads to Marrow Clearance in Resistant CLL

June 13, 2017

Complete marrow clearance of leukemic cells was achieved in 8 of 9 evaluable patients with heavily pretreated or genetically high-risk chronic lymphocytic leukemia who received concurrent treatment with CTL-119 cell therapy and ibrutinib, results of a pilot study showed.

Ublituximab Added to Ibrutinib Boosts ORR in Patients With Pretreated High-Risk CLL

June 07, 2017

Ublituximab (TG-1101) in combination with ibrutinib (Imbruvica) met its primary endpoint of showing an improvement in objective response rate (ORR) compared with ibruitinib monotherapy in patients with previously treated high-risk chronic lymphocytic leukemia (CLL). In a presentation of findings from the phase III GENUINE trial during the 2017 ASCO Annual Meeting, data were reviewed demonstrating that the combination had an ORR of 78% in this patient population.

Lenalidomide Consolidation Therapy in CLL Demonstrates Notable Survival Plateau

June 07, 2017

Lenalidomide consolidation therapy following induction with fludarabine and rituximab (Rituxan) was found to increase long-term survival over survival rates seen with FR or FR plus cyclophosphamide in an overall survival plateau that intrigued researchers when examined in patients with symptomatic, treatment-naive chronic lymphocytic leukemia without an 11q deletion.